ENLIVEN THERAPEUTICS, INC. Debt Securities, Available-for-sale
ENLIVEN THERAPEUTICS, INC. (ELVN) had Debt Securities, Available-for-sale of $759.65 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Assets
us-gaap:AvailableForSaleSecuritiesDebtSecurities · last filed 2026-08-05
- 2026-06-30: Debt Securities, Available-for-sale $759.65M.
- 2026-03-31: Debt Securities, Available-for-sale $320.22M.
- 2025-12-31: Debt Securities, Available-for-sale $363.73M.
- 2025-09-30: Debt Securities, Available-for-sale $375.83M.
| Period end | Debt Securities, Available-for-sale |
|---|---|
| 2026-06-30 | $759.65M 10-Q · filed 2026-08-05 |
| 2026-03-31 | $320.22M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $363.73M 10-Q · filed 2026-08-05 |
| 2025-09-30 | $375.83M 10-Q · filed 2025-11-12 |
| 2025-06-30 | $371.07M 10-Q · filed 2025-08-13 |
| 2025-03-31 | $187.85M 10-Q · filed 2025-05-14 |
| 2024-12-31 | $189.32M 10-K · filed 2026-03-03 |
| 2024-09-30 | $191.21M 10-Q · filed 2024-11-13 |
| 2024-06-30 | $215.52M 10-Q · filed 2024-08-13 |
| 2024-03-31 | $171.34M 10-Q · filed 2024-05-14 |
| 2023-12-31 | $153.01M 10-K · filed 2025-03-13 |
| 2023-09-30 | $189.63M 10-Q · filed 2023-11-09 |
| 2023-06-30 | $152.15M 10-Q · filed 2023-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 |